Patient and parent preferences for characteristics of prophylactic treatment in hemophilia

References

• BerntorpEJoint outcomes in patients with haemophilia: the importance of adherence to preventive regimensHaemophilia2009151219122719659939
   PubMed Web of Science ®Google Scholar
• BarrRDSalehMFurlongWHealth status and health-related quality of life associated with hemophiliaAm J Hematol200271315216012410568
   PubMed Web of Science ®Google Scholar
• SiboniSMMannucciPMGringeriAItalian Association of Haemophilia Centers (AICE). Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapyJ Thromb Haemost2009778078619220727
   PubMed Web of Science ®Google Scholar
• DeKovenMWisniewskiTPetrillaAHealth-related quality of life in haemophilia patients with inhibitors and their caregiversHaemophilia20131928729323005698
   PubMed Web of Science ®Google Scholar
• van den BergHMFischerKvan der BomJGComparing outcomes of different treatment regimens for severe haemophiliaHaemophilia20039suppl 12731 discussion 3112709034
   PubMed Web of Science ®Google Scholar
• CoppolaADi CapuaMDe SimoneCPrimary prophylaxis in children with haemophiliaBlood Transfus20086suppl 2S4S1119105503
   PubMedGoogle Scholar
• CoppolaATagliaferriADi CapuaMFranchiniMProphylaxis in children with hemophilia: evidence-based achievements, old and new challengesSemin Thromb Hemost201238799422314606
   PubMed Web of Science ®Google Scholar
• GringeriALeissingerCCortesiPAHealth-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA studyHaemophilia201319573674323731246
   PubMed Web of Science ®Google Scholar
• KhawajiMAstermarkJBerntorpELifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of lifeEur J Haematol20128832933522221195
   PubMed Web of Science ®Google Scholar
• MondorfWKalninsWKlamrothRPatient-reported outcomes of 182 adults with severe haemophilia in Germany comparing prophylactic vs. on-demand replacement therapyHaemophilia20131955856323560639
   PubMed Web of Science ®Google Scholar
• SchrammWRoyalSKronerBClinical outcomes and resource utilization associated with haemophilia care in EuropeHaemophilia20028334311886463
   PubMed Web of Science ®Google Scholar
• LiouWSTuTCChengSNSecondary prophylaxis treatment versus on-demand treatment for patients with severe haemophilia A: comparisons of cost and outcomes in TaiwanHaemophilia201117455420722742
   PubMed Web of Science ®Google Scholar
• AledortLMHaschmeyerRHPetterssonHA longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study GroupJ Intern Med19942363913997931042
   PubMed Web of Science ®Google Scholar
• RagniMVFogartyPJJosephsonNCNeffATRaffiniLJKesslerCMSurvey of current prophylaxis practices and bleeding characteristics of children with severe haemophilia A in US haemophilia treatment centresHaemophilia201218636821539695
   PubMed Web of Science ®Google Scholar
• OnoOSuzukiYYosikawaKAssessment of haemophilia treatment practice pattern in JapanHaemophilia2009151032103819476508
   PubMed Web of Science ®Google Scholar
• ThornburgCDCarpenterSZappaSMunnJLeissingerCCurrent prescription of prophylactic factor infusions and perceived adherence for children and adolescents with haemophilia: a survey of haemophilia healthcare professionals in the United StatesHaemophilia20121856857422335526
   PubMed Web of Science ®Google Scholar
• ThornburgCDPipeSWAdherence to prophylactic infusions of factor VIII or factor IX for haemophiliaHaemophilia20061219819916476098
   PubMed Web of Science ®Google Scholar
• De MoerloosePUrbancikWVan Den BergHMRichardsMA survey of adherence to haemophilia therapy in six European countries: results and recommendationsHaemophilia20081493193818684125
   PubMed Web of Science ®Google Scholar
• du TreilSRiceJLeissingerCAQuantifying adherence to treatment and its relationship to quality of life in a well-characterized haemophilia populationHaemophilia20071349350117880435
   PubMed Web of Science ®Google Scholar
• SaxenaKBarriers and perceived limitations to early treatment of hemophiliaJ Blood Med20134495623700376
   PubMedGoogle Scholar
• ZappaSMcDanielMMarandolaJAllenGTreatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns surveyHaemophilia201218e140e15322533455
   PubMed Web of Science ®Google Scholar
• FischerKVan Der BomJGPrejsRDiscontinuation of prophylactic therapy in severe haemophilia: incidence and effects on outcomeHaemophilia2001754455011851751
   PubMed Web of Science ®Google Scholar
• ShapiroADevelopment of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophiliaExpert Opin Biol Ther2013131287129723930915
   PubMed Web of Science ®Google Scholar
• LeeWCJoshiAVWoolfordSPhysicians’ preferences towards coagulation factor concentrates in the treatment of Haemophilia with inhibitors: a discrete choice experimentHaemophilia20081445446518282152
   PubMed Web of Science ®Google Scholar
• GelhornHMerikleEKrishnanSNemesLLeissingerCValentinoLPhysician preferences for medication attributes for the prophylactic treatment of patients with severe haemophilia A with inhibitors to factor VIIIHaemophilia20131911912523005041
   PubMed Web of Science ®Google Scholar
• ScaloneLMantovaniLGBorghettiFVon MackensenSGringeriAPatients’, physicians’, and pharmacists’ preferences towards coagulation factor concentrates to treat haemophilia with inhibitors: results from the COHIBA StudyHaemophilia20091547348619347988
   PubMed Web of Science ®Google Scholar
• MantovaniLGMonziniMSMannucciPMScaloneLVillaMGringeriADifferences between patients’, physicians’ and pharmacists’ preferences for treatment products in haemophilia: a discrete choice experimentHaemophilia20051158959716236108
   PubMed Web of Science ®Google Scholar
• BrownTMPashosCLJoshiAVLeeWCThe perspective of patients with haemophilia with inhibitors and their care givers: preferences for treatment characteristicsHaemophilia20111747648221091851
   PubMed Web of Science ®Google Scholar
• World Federation of HemophiliaReport on the Annual Gobal Survey 2013Montreal, Quebec, CanadaWordl Federation of Hemophilia2014
   Google Scholar
• KuhfeldWFTobiasRDGarrattMEfficient experimental design with marketing research applicationsJ Mark Res199431545557
   Web of Science ®Google Scholar
• RossiPEAllenbyGMMcCullochRBayesian Statistics and MarketingWest Sussex, EnglandJohn Wiley & Sons, Ltd2005
   Google Scholar
• Demia Studio AssociatoR-sw conjoint: a package for advanced conjoint analysis2012 Available from: http://www.demia.it/software-solution/r-sw-conjoint/Accessed December 15, 2012
   Google Scholar
• GreenPESrinivasanVConjoint analysis in consumer research: issues and outlookJ Consum Res19785103123
   Web of Science ®Google Scholar
• MahlanguJPowellJSRagniMVA-LONG InvestigatorsPhase 3 study of recombinant factor VIII fusion protein in severe hemophilia ABlood2014123331732524227821
   PubMed Web of Science ®Google Scholar
• TarantinoMDCollinsPWHayCRClinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia AHaemophilia200410542843715357767
   PubMed Web of Science ®Google Scholar
• ValentinoLAMamonovVHellmannAProphylaxis Study GroupA randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A managementJ Thromb Haemost20121035936722212248
   PubMed Web of Science ®Google Scholar
• PowellJSPasiKJRagniMVPhase 3 study of recombinant factor IX Fc fusion protein in hemophilia BN Engl J Med2013369242313232324304002
   PubMed Web of Science ®Google Scholar
• RothDAKesslerCMPasiKJHuman recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentratesBlood200198133600360611739163
   PubMed Web of Science ®Google Scholar
• PfizerPfizer announces positive top-line results from phase 3 study of NONACOG ALFA (BeneFIX®) once-weekly prophylaxis for hemophilia B [press release]2014716 Available from: http://press.pfizer.com/press-release/pfizer-announces-positive-top-line-results-phase-3-study-nonacog-alfa-benefix-once-weeAccessed October 6, 2015
   Google Scholar
• WindygaJLissitchkovTStasyshynOPharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia BHaemophilia2014201152423834666
   PubMed Web of Science ®Google Scholar
• LambertTRechtMValentinoLAReformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia BHaemophilia20071323324317498071
   PubMed Web of Science ®Google Scholar